Discover the must-see sessions at the 2025 Morningstar Investment Conference, from expert retirement insights to leadership ...

Used-car retailer CarMax logged higher profit and sales in its latest quarter as tariff uncertainty sparked an uptick in demand for used cars. It is the first time Rheinmetall will join the ...

Telomeres are the crucial protective caps at the ends of our DNA strands (they are sometimes compared to the plastic caps at the ends of shoelaces), and they are critical to cellular health. They ...

Looking at accelerated AI chip momentum and successful VMware integration, here’s what we think of Broadcom stock.

The upside in Brent that saw the August contract reach a high of just over $79/bbl translated into strong ULSD prices. The July diesel contract peaked at $2.695/gal, which represents the highest tick ...

The version of President Donald Trump's One Big Beautiful Bill Act passed by the House of Representatives in May calls for roughly $800 billion in cuts to Medicaid over 10 years. The version of the ...

The STOXX Europe 600 Index is down 8.41 points or 1.54% this week to 536.53 --Largest two week point and percentage decline since the week ending April 11, 2025 ...

During an interview with Joseph Adinolfi, Marko Papic, chief strategist at BCA Research, said that if Iran blocks the Strait of Hormuz in an attempt to disrupt the world oil market, investors should ...

From the end of May, the S&P 500 was up 1.5% in early trading on Friday. But many stocks of semiconductor manufacturers and providers of related computer hardware had soared by double digits.

Fed chief Jerome Powell, whose term ends next spring, has become a piñata for Trump. The president has repeatedly demanded the Fed lower rates and has assailed Powell publicly for not doing so.

Overall, retail sales rose 0.3% in April from a month earlier to a seasonally-adjusted 70.11 billion Canadian dollars, the equivalent of about $51.17 billion. That was softer than the 0.4% rise ...

The results for Lunsumio, also known as mosunetuzumab, and Polivy, also known as polatuzumab vedotin, came as part of a phase 3 study. Roche said it would now submit results to global health ...